Literature DB >> 17631470

[The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies].

Edit Bagoly1, Gergely Fehér, László Szapáry.   

Abstract

INTRODUCTION: It shows the importance of cerebrovascular diseases that they are the third main cause of death exceeded only by coronary artery diseases and cancer. Cerebral ischemia leads to irreversible brain damage, thereby it is important to rescue the hypoperfused areas. Patients without stroke but with chronic cerebral hypoperfusion can also benefit from the increasing of the cerebral blood flow.
METHODS: The aim of this review was to summarize the indications and the potential effects of vinpocetine in acute and chronic cerebrovascular diseases based on clinical studies.
RESULTS: There is no evidence that vinpocetine treatment is applicable in acute ischemic stroke, only few study with low patient number showed a slight but significant improvement in the patients conditions. In chronic cerebrovascular patients after single dose and long-term vinpocetine therapy, PET, TCD, SPECT and NIRS examinations showed increasing perfusion and elevated glucose and O 2 consumption of the examined areas, furthermore significant improvement of the rheologic factors was detected. A meta-analysis of international clinical studies showed a significant improvement in cognitive achievement in chronic stroke patients after oral therapy.
CONCLUSION: The cited studies showed the potential multi-pharmacological effects of vinpocetine and its beneficial hemorheological potential. The drug also improves the blood flow and the metabolism of the affected brain areas. There is increasing evidence that vinpocetine improves the quality of life in chronic cerebrovascular patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631470     DOI: 10.1556/OH.2007.28115

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  12 in total

1.  Vinpocetine inhibits Streptococcus pneumoniae-induced upregulation of mucin MUC5AC expression via induction of MKP-1 phosphatase in the pathogenesis of otitis media.

Authors:  Ji-Yun Lee; Kensei Komatsu; Byung-Cheol Lee; Masanori Miyata; Ashley O'Neill Bohn; Haidong Xu; Chen Yan; Jian-Dong Li
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

2.  Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism.

Authors:  Kye-Im Jeon; Xiangbin Xu; Toru Aizawa; Jae Hyang Lim; Hirofumi Jono; Dong-Seok Kwon; Jun-Ichi Abe; Bradford C Berk; Jian-Dong Li; Chen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-06       Impact factor: 11.205

3.  Vinpocetine Inhibits NF-κB-Dependent Inflammation in Acute Ischemic Stroke Patients.

Authors:  Fang Zhang; Chen Yan; Changjuan Wei; Yang Yao; Xiaofeng Ma; Zhongying Gong; Shoufeng Liu; Dawei Zang; Jieli Chen; Fu-Dong Shi; Junwei Hao
Journal:  Transl Stroke Res       Date:  2017-07-09       Impact factor: 6.829

4.  Vinpocetine attenuates lipid accumulation and atherosclerosis formation.

Authors:  Yujun Cai; Jian-Dong Li; Chen Yan
Journal:  Biochem Biophys Res Commun       Date:  2013-04-10       Impact factor: 3.575

5.  Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration.

Authors:  Yujun Cai; Walter E Knight; Shujie Guo; Jian-Dong Li; Peter A Knight; Chen Yan
Journal:  J Pharmacol Exp Ther       Date:  2012-08-22       Impact factor: 4.030

6.  Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial.

Authors:  Weiwei Zhang; Yining Huang; Ying Li; Liming Tan; Jianfei Nao; Hongtao Hu; Jingyu Zhang; Chen Li; Yuenan Kong; Yulin Song
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

7.  Vinpocetine Attenuates the Osteoblastic Differentiation of Vascular Smooth Muscle Cells.

Authors:  Yun-Yun Ma; Lin Sun; Xiu-Juan Chen; Na Wang; Peng-Fei Yi; Min Song; Bo Zhang; Yu-Zhong Wang; Qiu-Hua Liang
Journal:  PLoS One       Date:  2016-09-02       Impact factor: 3.240

8.  Vinpocetine protects against the development of experimental abdominal aortic aneurysms.

Authors:  Chongyang Zhang; Chia George Hsu; Amy Mohan; Hangchuan Shi; Dongmei Li; Chen Yan
Journal:  Clin Sci (Lond)       Date:  2020-11-27       Impact factor: 6.124

9.  Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE-/- mice.

Authors:  Jianhui Zhuang; Wenhui Peng; Hailing Li; Yuyan Lu; Ke Wang; Fan Fan; Shuang Li; Yawei Xu
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

10.  Vinpocetine attenuates neointimal hyperplasia in diabetic rat carotid arteries after balloon injury.

Authors:  Ke Wang; Li Wen; Wenhui Peng; Hailing Li; Jianhui Zhuang; Yuyan Lu; Baoxin Liu; Xiankai Li; Weiming Li; Yawei Xu
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.